Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1334 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Actual Study Start Date: November 1, 2012
Actual Primary Completion Date: April 20, 2017
Estimated Study Completion Date: March 1, 2020

Arms:
- Experimental: A + AVD
- Active Comparator: ABVD


Related journal:
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma